Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, it has spread rapidly around the globe and become a pandemic. Scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. However, what is the biochemical basis for current therapeutic and vaccine development strategies?
Join Angela Zhou, an Information Scientist at CAS, as she provides an overview of published scientific information relevant to COVID-19 research with an emphasis on patents in the CAS content collection. During this free interactive broadcast, she will highlight antiviral strategies involving small molecules and biologics targeting the complex molecular interactions involved in coronavirus infection and replication.
What You Will Learn
- Key proteins involved in SARS-CoV-2 infection which may serve as drug targets
- Drug-repurposing agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV
- Patent analysis of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines